Changsha Morning Shine Co., Ltd. is an innovative company dedicated to promoting quality advancements in the biopharmaceutical industry through robust chemical and biological underlying technologies. Our core businesses now encompass the development and manufacture of pharmaceutical raw materials and life science and diagnostic reagents, as well as outsourced services for pharmaceutical and biopharmaceutical research and development (R&D). Specially, our outsourced services cover contract research of chemical drug and biotechnology services, and with a leading edge in identification and preparation of challenging impurities, research on various trace impurities, and analysis of nucleic acids and proteins. In addition, our advantage products include peptide drug intermediates, nucleic acid chemical raw materials, monodisperse PEG derivatives, and dyes and labeling reagents.

With a core team comprising eminent professionals with extensive experience in pharmaceutical research and development, we have invested more than CNY100 million in state-of-the-art research instruments and equipment. Based on the comprehensive instrumentation and the cross-disciplinary team, we have established four advanced technical platforms: chemical synthesis, chemical analysis, chemical separation, and biotechnology. By fully leveraging the technical advantages of deep interdisciplinary integration of chemistry and biology, we focus on achieving breakthroughs in core technologies within the most critical areas of research and development.

Since our inception in 2019, we have garnered widespread recognition and trust from clients by consistently delivering well-grounded expertise, top-level services, and reliable products, and successfully entered into well-functioning partnerships with over 1000 global biopharmaceutical companies and research institutions. Adhering to the philosophy of pursuing excellence in quality through technological innovation, we are dedicated to being a leading provider of superior products and services in the upstream biopharmaceutical industry.